Parse Biosciences announced $41.5 million in funding this week. The Seattle-based biotech startup, which focuses on single-cell RNA sequencing, sets itself apart from other companies because its kits don’t rely on specialized equipment or devices, which ultimately improves usability.
“I think there’s a lot more excitement about research tools and realization about how enabling they are… We’re kind of in the golden age of research tools,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences.